HER-2 targeted immunonanoparticles for breast cancer chemotherapy

Journal of Applied Pharmaceutical Science

Volumn 1, Issue 3, 2011, Pages 132-139

  Dhankar, Ritu ^a   Rathee, Parmender ^b   Jain, Arvind K ^a   Arora, Sahil ^a   Kumar, Murugesan Senthil ^b   Rath, Goutam ^a   Saxena, Ajit Kumar ^c   Sharma, P R ^c   Chashoo, Gousia ^c   Goyal, Amit K ^a  

^a ISF COLLEGE OF PHARMACY   (India)

^b Rajendra Institute of Technology and Sciences   (India)

^c CSIR INDIAN INSTITUTE OF INTEGRATIVE MEDICINE   (India)

Author keywords

Anti HER 2 antibody; Breast cancer; Docetaxel; Immunonanoparticle; Nanoparticles

Indexed keywords

EID: 83555165816     PISSN: None     EISSN: 22313354     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Allen T. M. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2002; 2: 750-763.
2. Allen T. M., Cullis PR. Drug delivery systems: entering the mainstream. Science 2004; 303: 1818-1822.
3. Avgoustakis K. Pegylated Poly (Lactide) and Poly (Lactide-Co- Glycolide) nanoparticles: preparation, properties and possible applications in drug delivery. Curr. Drug Deliv. 2004; 1: 321-333.
4. Baulida J., Kraus M. H., Alimandi M., Fiore PPD., Carpenter G. All ErbB Receptors Other Than the Epidermal Growth Factor Receptor Are Endocytosis Impaired. J. Bio. Chem. 1996; 271: 5251-5257.
5. Capri G., Tarenzi E., Fulfaro F., Gianni L. The role of taxanes in the treatment of breast cancer. Semin. Oncol. 1996; 23: 68-75.
6. Chen P. C., Mwakwari S. C., Oyelere A. K. Gold nanoparticles: From nanomedicine to nanosensing. Nanotechnology, Science and Applications 2008; 1: 45-66.
7. Cirstoiu-Hapca A., Bossy-Nobs L., Buchegger F., Gurny R., Delie F. Differential tumor cell targeting of anti-HER2 (Herceptin®) and anti-CD20 (Mabthera®) coupled nanoparticles. Int. J. Pharm. 2007; 331: 190-196.
8. Fahmy T. M., Fong P. M., Goyal A., Saltzman W. M. Targeted for drug delivery. Mater. Today 2005; 8: 18-26.
9. Feng S. S., Chien S. Chemotherapeutic engineering: Application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chem. Eng. Sci. 2003; 58: 4087-4114.
10. Frankel A. E. New HER2- directed therapies for breast cancer. Clin. Cancer Research 2002; 8: 1699-1701.
11. Funaro A., Horenstein A. L., Santoro P., Cinti C., Gregorini A., Malavasi F. Monoclonal antibodies and therapy of human cancers. Biotechnol. Adv. 2000; 18: 385-401.
12. Garnett M. C. Targeted drug conjugates: principles and progress. Adv. Drug Del. Rev. 2001; 53: 171-216.
13. Harari D., Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 2000; 19: 6102-6114.
14. Illum L., Davis S. S. The effect of hydrophilic coatings on the uptake of colloidal particles with mouse peritoneal macrophages. Int. J. Pharm. 1986; 29: 53-61.
15. Illum L., Davis S. S., Muller R. H., Mark E., West P. The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with blockcopolymer polaxamine 908. Life Sci. 1987; 40: 367-374.
16. Kaye S. B. Taxoids. Eur. J. Cancer 1995; 31A: 824-826.
17. Kocbek P., Obermajer N., Cegnar M., Kos J., Kristl J. J. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. Control. Rel. 2007; 120: 18-26.
18. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-497.
19. Kohli E., Huai-Yun H., Arin, Zeman D., Vinogradov S. V. Formulations of biodegradable Nanogel carriers with 5'- triphosphates of nucleoside analogs that display a reduced cytotoxicity and enhanced drug activity. J. Control. Rel 2007; 121: 19-27.
20. Lambert J. M. Drug-conjugated monoclonal antibodies for treatment of cancer. Curr. Opin. Pharmacol. 2005; 5: 543-549.
21. Mu L., Feng S. S. A novel controlled release formulation for the anticancer drug Paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J. Control. Rel. 2003; 86: 33-48.
22. Nahar M., Dutta T., Murugesan S., Asthana A., Mishra D., Rajkumar V., Tare M., Saraf S., Jain N. K. Functional polymeric nanoparticles: an efficient and promising tool for active delivery of bioactives. Crit. Rev. Ther. Drug Carrier Syst. 2006; 23: 259-318.
23. Nair P. Epidermal growth factor receptor family and its role in cancer progression. Current Sciences 2005; 88: 890-898.
24. Porter C. J., Moghimi S. M., Illum L., Davis S. S. The polyoxyethylene/ polyoxypropylene block co-polymer polaxamer-407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow. FEBS Lett. 1992; 305: 62-66.
25. Rowinsky E. K. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu. Rev. Med. 1997; 48: 353-374.
26. Sapra P., Allen T. M. Ligand-targeted liposomal anticancer drug. Prog. Lipid Res. 2003; 42: 439-462.
27. Senthilkumar M., Subramanian G., Ranjitkumar A., Nahar M., Mishra P., Jain N. K. PEGylated poly(lactide-co-glycolide) (PLGA) nanoparticulate delivery of Docetaxel: Synthesis of diblock copolymers, optimization of preparation variables on formulation characteristics and in vitro release studies. J. Biomed. Nanotech. 2007; 3: 52-60.
28. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J. T., Bokesch H., Kenney S. and Boyd M. R. New colorimetric cytotoxicity assay for anticancerdrug screening. J. Natl. Cancer Inst. 1990; 82: 1107-1112.
29. Slamon D. J., Clark G. M., Wong S. G., Levin W. J., Ullrich A., McGuire W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER- 2/neu oncogene. Science 1987; 235: 177- 82.
30. Steinhauser I., Spankuch B., Strebhardt K., Langer K. Trastuzumab-modified nanoparticles: Optimisation of preparation and uptake in cancer cells. Biomaterials 2006; 27: 4975-4983.
31. Sun B., Ranganathan B., Feng S. S. Multifunctional poly (D, L- lactide-co glycolide) /montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. Biomaterials 2008; 29: 475-486.
32. Trail P. A., Bianchi A. B. Monoclonal antibody drug conjugates in the treatment of cancer. Curr. Opin. Immunol. 1999; 11: 584-588.
33. Trail P. A., King H. D., Dubowchik G. M. Monoclonal antibody drug Immunoconjugates. Cancer Immunol. Immunother. 2003; 52: 328-337.
34. Vasir J. K., Labhasetwar V. Targeted Drug Delivery in Cancer Therapy. Technology in Cancer Research & Treatment 2005; 5: 363-374.
35. Widakowich C., Azambuja E., Gil T., Cardoso F., Dinh P., Awada A., Piccart-Gebhart M. Molecular targeted therapies in breast cancer: Where are we now. International J. Biochem. & Cell Biol. 2007; 39: 1375-1387.
36. Yoon J. J., Nam Y. S., Kim J. H., Park T. G. Surface immobilization of galactose onto aliphatic biodegradable polymers for hepatocytes culture. Biotech. Bioeng. 2002; 78: 1-10.
37. Zhang Z. P., Lee S. H., Feng S. S. Folate-decorated poly (lactide-coglycolide)- vitamin E TPGS nanoparticles for targeted drug delivery. Biomaterials 2007; 28: 1889-1899.